Pulse Biosciences (NASDAQ:PLSE) Trading Up 3.3% – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares traded up 3.3% during trading on Wednesday . The stock traded as high as $56.74 and last traded at $54.4380. Approximately 132,644 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 382,722 shares. The stock had previously closed at $52.69.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. BTIG Research began coverage on Pulse Biosciences in a research note on Wednesday. They issued a “buy” rating and a $70.00 price target for the company. Canaccord Genuity Group upped their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research note on Monday, August 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.20.

Pulse Biosciences Stock Performance

The stock has a market capitalization of $3.77 billion, a P/E ratio of -45.11 and a beta of 1.63. The business has a 50 day simple moving average of $43.94 and a 200-day simple moving average of $30.75.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Equities research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Transactions at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,036 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were purchased at an average cost of $48.23 per share, with a total value of $49,966.28. Following the completion of the acquisition, the chief operating officer directly owned 1,036 shares in the company, valued at approximately $49,966.28. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 4,095 shares of company stock worth $199,931 over the last quarter. 74.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently made changes to their positions in PLSE. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences in the 2nd quarter worth approximately $28,000. Jupiter Topco LLC bought a new stake in Pulse Biosciences during the second quarter worth approximately $241,000. GSA Capital Partners LLP acquired a new position in Pulse Biosciences in the second quarter worth approximately $290,000. Cetera Investment Advisers bought a new position in shares of Pulse Biosciences in the first quarter valued at $387,000. Finally, Legal & General Group Plc bought a new position in shares of Pulse Biosciences in the second quarter valued at $395,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.